A comparability exercise is a structured demonstration that a biopharmaceutical product remains comparable to the original product following a change in the manufacturing process, at a new site, or after scaling. The objective is to show that quality, safety, and efficacy are not clinically significantly affected by the change. Comparability is thus a central concept in the manufacturing of biologics and biosimilars, as well as in advanced process development and life-cycle changes.
In practice, changes occur frequently: new cell banks, modified purification steps, new filling or packaging processes, different reference materials, or optimized formulations. Since biologics are highly complex and possess sensitive quality attributes, a mere process description is insufficient. A comparability exercise combines analytical, functional, and, if necessary, non-clinical and clinical data to demonstrably link the product before and after the change.
Why comparability is so important for biologics
Biologics are heterogeneous molecules (e.g., monoclonal antibodies) with critical quality attributes such as glycosylation, aggregates, charge variants, or biological activity. Even minor process changes can shift these attributes. If the differences were clinically relevant, immunogenicity, pharmacokinetics, or efficacy could be affected. Therefore, regulatory authorities require that changes be assessed on a risk-based basis and supported by appropriate data.
For companies, comparability is also a business matter: scaling and site transfers are often necessary to meet demand or increase resilience. Robust evidence of comparability prevents the need to repeat clinical programs and reduces the risk of supply interruptions.
Typical triggers: Process changes, scale-up, site transfers
Common triggers include: scale-up from clinical to commercial scale, switching from single-use to stainless steel systems, optimization of fermentation conditions, changes in raw materials or suppliers, and the introduction of new analytical methods. Methodological changes may also require a new assessment if the measurement principle or sensitivity affects comparability.
Planning should occur early and be closely coordinated with quality management, regulatory affairs, and pharmacovigilance. Insufficient evidence can lead to delays in variations, regulatory requirements, or additional batch and stability studies that tie up time and resources.
A common practical error is a too narrow focus on specifications: comparability is not identical to being “within specification.” The decisive factor is whether differences between manufacturing states could plausibly influence clinical performance. Therefore, a scientific justification of critical quality attributes and their clinical relevance is more important than a purely formal comparison of specifications.
Stepwise approach: Analytics first, then functional and, if necessary, clinical
The basic principle is: demonstrate as much as possible analytically and functionally, and as little as necessary clinically. Initially, extensive characterizations are performed, including structural and purity analysis, process- and product-related impurities, and stability data. This is followed by biofunctional tests, such as binding assays, cell-based potency assays, or complement activation, to reflect biological activity.
If relevant uncertainties remain after these steps, supplementary non-clinical or clinical data may be required. This may concern, for example, comparative pharmacokinetics or immunogenicity. For biosimilars, the concept of comparability is central to the entire development program and serves as a methodological reference framework.
A practical point is batch selection: to reflect natural variability, several representative batches from both manufacturing states should be compared. Bridging between analytical methods (old vs. new) must also be carefully planned so that differences do not arise as artifacts. Additionally, it must be clarified how reference standards and stability programs support the interpretation.
If differences are identified, a structured impact assessment step should follow: Which quality attributes are affected, which mechanisms are plausible, and what additional data (e.g., extended potency assays or stress studies) reduce uncertainty? This logic is often the decisive part in audits and regulatory inquiries.
Documentation and submission: From report to variation
The results are typically consolidated in a comparability protocol or report. This documents the description of the change, risk assessment, study design, acceptance criteria, and an integrated conclusion. It is important that deviations are not viewed in isolation but in the context of clinical relevance and the overall data situation.
For EU marketing authorizations, the submission is usually made as a variation. Early scientific advice can be useful if the change is complex or if the analytics do not allow for a clear conclusion. In Germany, additional national aspects such as inspection requirements, QP release, and interfaces with the EU GMP system are relevant.
From an organizational perspective, roles, responsibilities, and decision-making paths should be documented: who defines acceptance criteria, who evaluates deviations, who approves the submission, and how results are fed back into life-cycle management. Clear governance prevents technical and regulatory teams from working with different assumptions. For global programs, regional requirements (e.g., EU, USA, Japan) must also be harmonized to enable consistent variation strategies.
FAQ and regulatory references
When is a comparability exercise required?
Whenever a manufacturing or process change can potentially affect critical quality attributes, e.g., during scale-up, site transfers, or changes in formulation.
Is analytical comparability sufficient?
Often yes, if analytics and functional tests convincingly demonstrate similarity. If uncertainties remain, additional non-clinical or clinical data may be necessary.
How is comparability related to biosimilars?
For biosimilars, comparative similarity to the reference product is the central principle. A comparability exercise for process changes follows the same stepwise approach but refers to the company’s own product before and after the change.
- ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process
- EU GMP Guidelines (EudraLex Volume 4) and variation rules for regulatory changes
- EMA guidelines on quality changes and comparative assessment for biologics